Biology subjects

Kang, H. G.

Publications and source records attributed to Kang, H. G..

8 recordsLinked to original sources

bioRxiv2026

Longitudinal transcriptomic analysis reveals adaptive transcript usage remodeling associated with PARP inhibitor resistance

Poly (ADP-ribose) polymerase inhibitors (PARPi) have revolutionized the treatment of ovarian and breast cancers with homologous recombination deficiency (HRD). Despite substantial initial efficacy, the frequent development of acquired resistance poses a critical clinical challenge, necessitating a deeper understanding of the underlying molecular mechanisms. While genomic profiling provides information on baseline HRD status, it is insufficient to capture the dynamic and functional adaptations accompanying resistance during treatment. In this study, we investigated the role of alternative splicing in PARPi resistance using longitudinal pre- and post-treatment RNA-sequencing data from an ovarian cancer patient cohort (n=40). We demonstrated that profiling alternative splicing dynamics and differentially used transcripts (DUTs) provides transcriptomic insights distinct from conventional differential gene expression analysis. Notably, we observed significant differences between acquired resistance (AR) and innate resistance (IR) groups. Specifically, longitudinal analysis revealed that AR tumors exhibit a distinct transcript usage pattern, characterized by an increase in canonical protein-coding transcripts involved in cell-cycle processes and a decrease in non-canonical non-coding transcripts within the homologous recombination pathway following treatment. Extending this comparison across AR and IR tumors at both pre- and post-treatment stages, these transcriptomic features were most pronounced in the AR post-treatment group. Further analysis of subsequent treatment outcomes showed that, among AR patients, greater resistance-associated transcriptomic remodeling was associated with poorer response and shorter progression-free survival. The resistance-associated transcriptomic signatures identified through longitudinal profiling were further recapitulated in an independent pre-treatment cohort (n=71; 43 AR and 28 IR), with more pronounced differences among BRCA wild-type patients. Taken together, our findings identify differential transcript usage as dynamic transcriptomic features associated with acquired PARPi resistance and establish a framework for utilizing longitudinal transcriptome dynamics to investigate the molecular basis of clinical drug resistance.

cancer biology↗

bioRxiv2026

Splicing of ultraconserved poison exons controls mitotic fidelity and stem cell viability

SR proteins are essential splicing regulators whose expression is controlled in part through poison exons (PEs) -- ultraconserved non-coding exons that trigger nonsense-mediated decay -- yet the biological functions of these elements remain undefined. Here, we show that homozygous deletion of SRSF3-PE or TRA2{beta}-PE is selected against in mouse embryos and human induced pluripotent stem cells (iPSCs), and that conditional PE deletion causes apoptotic death in iPSCs but is tolerated in post-mitotic neurons, revealing a proliferative-state-specific requirement. Mechanistically, PE deletion elevates SR protein levels, triggers widespread splicing dysregulation, and disrupts the correct splicing of a mitotic gene network associated with spindle defects and mitotic errors. These findings establish ultraconserved poison exons as essential regulators of mitotic splicing fidelity and stem cell viability.

molecular biology↗

bioRxiv2026

CD99Targeted Irinotecan Containing Nanoparticles Show Twenty-Fold Greater Anti-Tumor Effect Than Free Irinotecan For Treatment of EwingSarcoma

PurposeTo assess the antitumor efficacy, pharmacokinetics, and safety of NV103, a CD99-targeted liposomal irinotecan nanoparticle, in a preclinical Ewing sarcoma model. Experimental DesignNV103 is a CD99-antibody targeted irinotecan containing nanoparticle, engineered to selectively deliver irinotecan to CD99 expressing tumor cells. In vitro studies measured binding, internalization, and cytotoxic IC50 values in several Ewing sarcoma cell lines. In vivo, mice bearing xenografts derived from treatment-naive and chemoresistant Ewing lines were treated. NV103 was compared with free irinotecan, untargeted nanoparticles, and OnivydeTM at multiple dosages. Plasma pharmacokinetics of irinotecan and SN-38, biodistribution of the nanoparticles, and toxicity (body weight, organ function, and hematology) were assessed. ResultsNV103 bound selectively to tumor cells (>80x over control), was rapidly internalized, and showed enhanced potency in vitro (IC50 {approx} 3-4 nM at 0.5-1 h). In vivo, biweekly dosing at 5 mg/kg resulted in full tumor regression sustained for 140 days, even after stopping treatment at day 70. Effective suppression and survival benefit were observed at doses as low as 1 mg/kg; the ED50 was estimated to be between 1-2.5 mg/kg versus 50mg/kg for free irinotecan. In a chemoresistant Ewing tumor cell line, NV103 induced similar tumor-free remission. Pharmacokinetics revealed prolonged and elevated plasma levels of irinotecan with NV103 versus free drug. No systemic toxicity was detected at doses of 10 mg/kg. Biodistribution showed tumor-preferential accumulation. ConclusionsNV103 displays potent and durable antitumor activity in Ewing sarcoma at low doses with no toxicity and favorable pharmacokinetics. These findings support further development for clinical translation. Translational RelevanceAlthough Irinotecan has shown activity against Ewing sarcoma, its clinical utility is limited by systemic toxicity and poor tumor selectivity. NV103, a CD99-targeted nanoparticle formulation of irinotecan delivers irinotecan selectively to Ewing sarcoma cells. CD99 is a surface antigen that is highly expressed in Ewing sarcoma cells but largely absent from irinotecan-sensitive organs like liver, kidney, and bone marrow. In preclinical xenograft models, NV103 induced complete and durable tumor regression at doses >10 fold lower than those of free irinotecan or untargeted nanoparticles, with no detectable systemic toxicity. These findings suggest that NV103 is a promising translational therapeutic agent that enhances the therapeutic index of irinotecan and other cytotoxic agents. This platform offers a broadly adaptable approach to tumor-specific drug delivery, which could significantly improve treatment outcomes and reduce long-term toxicity in children and young adults with Ewing sarcoma and other solid tumors.

cancer biology↗

bioRxiv2025

SpliceDecoder: A High-Throughput Tool for Guiding the Functional Interpretation of Differential Splicing Events

Alternative splicing generates different mRNA isoforms from single genes, generating protein diversity essential for normal development and tissue function. Dysregulation of splicing is implicated in numerous diseases, including cancer, neurodegeneration, diabetes, and rare genetic disorders. Although thousands of spliced isoforms have been identified in disease-relevant contexts, the functional significance of most remains unknown, hindering our understanding of splicing-driven disease mechanisms and limiting therapeutic discovery. A major challenge lies in prioritizing biologically meaningful splicing events identified through short-read RNA sequencing. Existing splicing analysis tools typically rank target events based on splicing change magnitude or gene-level annotation, often without evaluating how resulting isoforms impact protein structure or function. This creates a critical bottleneck in translating splicing data into biological and therapeutic insights. To address this, we developed SpliceDecoder, a computational workflow that predicts how each splicing event or isoform impacts transcript productivity, protein sequence, and functional domains. Each event is assigned a functional effect score to guide evidence-based prioritization. SpliceDecoder facilitates a more informed interpretation of splicing data, reduces reliance on prior knowledge, and enables identification of events with potential biological and clinical relevance. We demonstrate its utility by validating known splicing alterations and identifying novel disease-associated isoform switches across public datasets.

genomics↗

bioRxiv2025

Host-specific bacterial modulation of airway gene expression and alternative splicing

The human microbiome varies extensively between individuals. While there are numerous studies investigating the effects of inter-individual differences on microbiome composition, there are few studies investigating inter-individual effects on microbial modulation of the host, or host-specific effects. To address this knowledge gap, we colonized human bronchial epithelial air-liquid interface tissue cultures generated from six different adults with one of three phylogenetically diverse bacteria and compared how each microbe differentially modulated host gene expression in each of the six donors. Microbial treatment had the strongest effect on transcription, followed by donor-specific effects. Gene pathways differed markedly in their donor- and microbe-specificity; interferon expression was highly donor-dependent while transcription of epithelial barrier and antibacterial innate immunity genes were predominantly microbially driven. Moreover, we evaluated whether microbial regulation of alternative splicing was modulated by donor. Strikingly, we found significant non-redundant, donor-specific regulation of alternative splicing exclusively in the Gram-positive commensal microbes. These findings highlight that microbial effects on the human airway epithelium are not only species-specific but also deeply individualized, scoring the importance of host context in shaping microbe-induced transcriptional and splicing responses.

microbiology↗

bioRxiv2025

Boosting Antitumour Efficacy and Immunity by Boron Neutron Capture Therapy with Size-Controlled Nanoparticles

Boron neutron capture therapy (BNCT) is emerging cancer radiotherapy requiring 10B sensitizer. Although boronophenylalanine (BPA)-BNCT is approved clinically in Japan, the low tumour selectivity and retentivity result in the long-time infusion of high doses. Based on our finding of the size-controllable mechanochemical synthesis of boron-10 carbide nanoparticles (10B4C NPs), the 50 nm size NPs grafted with poly(glycerol), {superscript 1}BC(50)-PG, is found to show superior tumour selectivity and retentivity to enhance the eradication efficacy at much lower dosage (5 mg [10B] / kg (mouse)). The dosage is further reduced by twice neutron irradiation or combination with an immune checkpoint inhibitor (ICI). Antitumour immunity is found to be boosted by {superscript 1}BC(50)-PG-BNCT to induce abscopal effect to treat remote or metastatic tumours and long-term memory to prevent cancer recurrence. Additionally, minimal side effects and gradual NP excretion are observed for one year. The 10B4C(50)-PG is concluded to be a promising 10B carrier for clinical application of BNCT due to the prominent antitumour efficacy and immune-activation with minimal toxicity.

cancer biology↗

bioRxiv2025

Heartbeat-like dynamics drives oxygen activation in methane monooxygenase

Soluble methane monooxygenase (sMMO) is an enzyme that hydroxylates methane (CH4), a potent greenhouse gas, at non-heme di-iron active sites under atmospheric conditions. The regulatory component (MMOB) is essential for the catalytic activity of hydroxylase (MMOH) as it induces conformational changes in the active site and facilitating substrate ingress. Recent advances in cryogenic electron microscopy (cryo-EM) have enabled us to elucidate the high resolution picture of sMMO catalytic mechanism. We describe the 2.85 [A] cryo-EM structure of MMOH-MMOB, with one equivalent of MMOB bound to MMOH (H-1B), which is in contrast with previously solved crystal structures. MMOB allosterically regulates the MMOH protomer ({beta}{gamma}) and induces conformational changes that propagate from the surface to the di-iron coordination site. The N-terminal region of the MMOH {beta}-subunit (NT-H{beta}) stabilizes helices essential for iron coordination and oxygen activation. The MMOB-bound protomer (HBA, {beta}{gamma}B) presents the first structural report of a 2.7 [A] Fe{middle dot}{middle dot}{middle dot}Fe distance, while the non-MMOB-bound protomer (HBB, {beta}{gamma}) and MMOH display a 3.1 [A] distance. The coordination of Fe-ligands is maintained by the structural stabilization provided by the {beta}- and {gamma}-subunits of MMOH. This novel cryo-EM structure reveals new coordination environments, offering crucial mechanistic insights into sMMO catalysis.

biochemistry↗

bioRxiv2023

Comprehensive single cell aging atlas of mammary tissues reveals shared epigenomic and transcriptomic signatures of aging and cancer

Aging is the greatest risk factor for breast cancer; however, how age-related cellular and molecular events impact cancer initiation is unknown. We investigate how aging rewires transcriptomic and epigenomic programs of mouse mammary glands at single cell resolution, yielding a comprehensive resource for aging and cancer biology. Aged epithelial cells exhibit epigenetic and transcriptional changes in metabolic, pro-inflammatory, or cancer-associated genes. Aged stromal cells downregulate fibroblast marker genes and upregulate markers of senescence and cancer-associated fibroblasts. Among immune cells, distinct T cell subsets (Gzmk+, memory CD4+, {gamma}{delta}) and M2-like macrophages expand with age. Spatial transcriptomics reveal co-localization of aged immune and epithelial cells in situ. Lastly, transcriptional signatures of aging mammary cells are found in human breast tumors, suggesting mechanistic links between aging and cancer. Together, these data uncover that epithelial, immune, and stromal cells shift in proportions and cell identity, potentially impacting cell plasticity, aged microenvironment, and neoplasia risk.

genomics↗